MichaelDKaufmanMD

PubMed

• 454 citations
  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
  Jeffrey F. Ohren, Huifen Chen, Alexander Pavlovsky, Christopher Whitehead, Erli Zhang
  Nature Structural & Molecular Biology. 2004-11-14
• 62 citations
  Multiple sclerosis: severity and progression rate in African Americans compared with whites.
  Michael Kaufman, Susan K. Johnson, David Moyer, Jessica Bivens, H. James Norton
  American Journal of Physical Medicine & Rehabilitation. 2003-08-01
• 210 citations
  The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
  Stephen Douglas Barrett, Alexander James Bridges, David T. Dudley, Alan R. Saltiel, James H. Fergus
  Bioorganic & Medicinal Chemistry Letters. 2008-12-15

Journal Articles

• MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study  
  Fox RJ, Cree BA, De Seze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P, Neurology, 1/1/2014
• HLA DR and DQ predict response to glatiramer acetate in multiple sclerosis  
  Dhib-Jalbut S, Valenzuela RM, Ito K, Kaufman M, Picone M, Buyske S, Mult Scler Rel Dis, 1/1/2013
• Course of relapsing-remitting MS before, during, and after natalizumab  
  Kaufman MD, Lee R, Norton HJ, Multiple Sclerosis J, 1/1/2011
• Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta  
  Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O’Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, for the CHOICE investigators, Lancet Neurol, 1/1/2010
• Mitoxantrone in the treatment of multiple sclerosis in African Americans compared to Caucasians with secondary progressive multiple sclerosis  
  Moore L, Kaufman M, Conway J, Int J MS Care, 1/1/2010
• Health-related quality of life among young adults with multiple sclerosis  
  Buchanan RJ, Huang CF, Kaufman M, Int J MS Care, 1/1/2010
• Relationships between information processing, depression, fatigue and cognition in multiple sclerosis  
  Diamond BJ, Johnson SK, Kaufman M, Graves L, Arch Clin Neurppsychol, 1/1/2008
• Neurologists versus non-neurologists Care of multiple sclerosis patients  
  Buchanan RJ, Kaufman M, Zhu L, James W, Int J MS Care, 1/1/2008
• Patient perceptions of multiple sclerosis-related care: Comparisons by practice specialty of principal care physician  
  Buchanan RJ, Kaufman M, Zhu L, James W, NeuroRehabilitation, 1/1/2008
• Examining the effects of stressors and resources on multiple sclerosis among African Americans and Whites  
  Johnson SK, Terrell T, Sargent C, Kaufman M, Stress and Health, 1/22/2007
• Adherence to therapy: using an evidence-based protocol  
  Moore LA, Kaufman MD, Algozzine R, Irish N, Martin M, Posey CR, Rehabilitation Nursing, 1/1/2007
• Coping with MS: How to give patients their lives back  
  Kaufman, M, Practical Neurology, 1/1/2007
• Juvenile Metachromatic Leurkodystrophy Mimicking Relapsing-Remitting Multiple Sclerosis  
  Kaufman M, Parrott JH, Int J MS Care, 1/1/2006
• The effect of gingko biloba on functional measures in multiple sclerosis: A pilot randomized controlled trial  
  Johnson, S.K., Diamond, B.J., Rausch, S., Kaufman, M., Schiflett, S., & Graves, L, EXPLORE: The Journal of Science and Healing, 1/1/2006
• Perspective from Practice  
  Kaufman MD, Neura, Quarterly Column, 1/1/2005
• Longitudinal assessment of multiple sclerosis patients and reimbursement issues  
  Kaufman M, Cutter G, Schwid S, Johnson K, Halper J, Birnhaum G, et al, Int J MS Care, 1/1/2005
• Multiple Sclerosis: Severity and Progression Rate in African Americans Compared with Whites  
  Kaufman MD, Moyer D, Bivens J, Johnson S, Am J Phys Med Rehabil, 1/1/2003
• Book review: Herndon RM Multiple Sclerosis: Immunology, Pathology, and Pathophysiology Demos Medical Publishing, Inc, New York, 2003  
  Kaufman MD, Int. J. MSCare, 1/1/2003
• Is C pneumoniae Found in Spinal Fluid Samples from MS Patients? Conflicting Results  
  Kaufman MD, Gaydos C, Sriram S, Boman J, Tondella ML, Norton HJ, Multiple Sclerosis, 1/1/2002
• A Randomized Controlled Safety Trial of Interferon beta-1a and Oral Cyclophosphamide in MS  
  Kaufman M, Norton HJ, Sonnenfeld G, Int J MSCare, 1/1/2002
• Combining Therapies with IFN beta for Relapsing and Early Progressive MS: A Review  
  Kaufman M, Int J MSCare, 1/1/2002
• The significant change for the Timed 25-foot Walk in the Multiple Sclerosis Functional Composite  
  Kaufman MD, Moyer D, Norton J, Multiple Sclerosis, 1/1/2000
• Multiple Sclerosis: Diagnosis, medical management and rehabilitation Demos, New York, 2000  
  Kaufman MD, Int. J. MSCare, 1/1/2000
• Ishihara's tests for color blindness: a useful indicator of visual involvement in multiple sclerosis  
  Kaufman MD, Lutz DM, Norton J, Int J MSCare, 1/1/2000
• A controlled investigation of bodywork in multiple sclerosis  
  Johnson S, Fredericks J, Kaufman MD, J Alternative & Complementary Medicine, 1/1/1999
• Join now to see all

Books/Book Chapters

• Medlink (on-line text of neurology). 
  Chapter: Balo Concentric Sclerosis. 
  Kaufman MDEditors: Sid Gilman.2009
• Medlink (on-line text of neurology). 
  Chapter: Treatment of Multiple Sclerosis Symptoms. 
  Kaufman MDEditors: Richard Johnson.2002
• Proceedings. Fourth Meeting of the European Society for Chlamydia research, Helsinki, Finland. 
  Chapter: Lack of detection of Chlamydia Pneumoniae by PCR and tissue culture in cerebrospinal fluid from multiple sclerosis patients and controls. 
  Theodore M, Kaufman M, Wagar E, Myers L, Quinn TC, Gaydos CAEditors: Pekka Saikku.Societa Editrice Esculapio, Bologna, Italy2000
• HSSA-Editorial, Neurology Board Review, Education Division 
  Chapter: Multiple Sclerosis. 
  Kaufman MDEditors: American Academy of Family Physicians.1999
• Saunders Manual of Medical Practice 
  Chapter: Multiple Sclerosis. 
  Page 1058 - 1060Kaufman MDEditors: Rakel RE.Saunders Co, Philadelphia, PA1996
• Encyclopedia of Clinical Neuropsychology. 
  Chapter: Neuropathy 
  Kaufman MDEditors: Kreutzer JS, DeLuca J, Caplan B.Springer, Heidelberg, Germany
• Join now to see all

Abstracts/Posters

• Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNbeta-1a in RRMS patients. Poster
  Douglas L Arnold, Ludwig Kappos, Eva Havrdova, Krzysztof Selmaj, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Katherine Rie..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
• Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis.
  Krzysztof Selmaj, Ludwig Kappos, Douglas L. Arnold, Eva Havrdova, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Katherine Ri..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
• Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of Daclizumab HYP vs. Interferon beta-1a in RRMS patients.
  Ludwig Kappos, Krzysztof Selmaj, Douglas Arnold, Eva Havrdova, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Marianne Sweets..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
• Motor Deficit Evaluated by Timed Functional Measures Correlate with Functional Rating Scale Used in Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), bu...
  Sanjak M, Mays J, Hirsch M, Englert D, Iyer S, Conway J, Kaufman M, Bravver E, Brooks B, American Academy of Neurology 65th annual meeting, San Diego, CA, 1/1/2013
• Natalizumab Effects During a 6-Month Dose Interruption: Relationship of Pharmacokinetic (PK), Pharmacodynamic (PD), and MRI Measurements.
  Cree, B, De Seze J, Fox R, Gold R, Hartung H-P, Jeffery D, Kappos L, Kaufman M, Montalban X, Weinstock-Guttman B, Woodworth J, Plavina T, Duda P, American Academy of Neurology 65th annual meeting, San Diego, CA, 1/1/2013
• The Joint Commission TJC/Disease-Specific Care (DSC) Certification Programs for Parkinson's Disease (PD)/Multiple Sclerosis (MS)/ Amyotrophic Lateral Sclerosis (ALS) -...
  Conway J, Englert D, Bravver E, Craig C, williams N, Cashdollar S, Price M, Fortier C, Kaufman M, Brooks B, Iyer S, American Academy of Neurology 65th annual meeting, San Diego, CA, 1/1/2013
• Observations on the design of secondary progressive MS trials.
  Kaufmann L, Moore M, Kaufman M, Lutz D, Norton J, Cooperative Meeting of the Consortium of MS Centers and the Americas Committee for Treatment and Research in MS, San Diego, CA, 1/1/2012
• RESTORE study: Effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity.
  Cree B et al, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Effects of a 24-week natalizumab treatment interruption on quality of life, fatigue, and cognition: results from the RESTORE study.
  Weinstock-Guttman B et. al, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study.
  Fox R, Kappos L, Cree B, Kaufman M, Jeffery D, Weinstock-Guttman B, Hartung H-P, Gold R, Montalban X, De Seze J, Natarajan A, Morse R, Ticho B, Duda P, ECTRIMS, 1/1/2011
• Decide rationale/design: daclizumab high yield process monotherapy in relapsing remitting multiple sclerosis (RRMS).
  Kappos L, Wiendl H, Kaufman M, et al, Eur J Neurol, 1/1/2010
• DECIDE rationale and design: Daclizumab high-yield process monotherapy in RRMS.
  Kappos L, Wiendl H, Kaufman MD, Rose JW, Hardova W, et al, Annual meeting Consortium of MS Centers, San Antonio, TX, 1/1/2010
• Predictive biomarkers of clinical response to glatiramer acetate (GA) therapy in multiple sclerosis MS. Poster
  Valenzuela RM, Kaufman M, Russo P, Picone M, Halper J, Costello K, Rosaria Y, Ito K, Dhib-Jalbut S, 61st Annual Meeting of the American Academy of Neurology, Seattle, WA, 1/1/2009
• Functional and clinical assessment before and after mitoxantrone.
  Moore LA, Kaufman MD, Edinger A, Consortium of MS Centers Annual Meeting, Denver, CO, 1/28/2008
• A phase 2, randomized, double-blind, placebo-controlled, multicenter study of subcutaneous dacluzumab in patients with active relapsing forms of multiple sclerosis – w...
  K aufman M, Wynn D, Montalban X, Wang M, Fong A, Contemporary Clinical Issues and Case Studies Plenary Session, 60th Annual Meeting of the American Academy of Neurology, Chicago, IL, 1/16/2008
• Perceptions of Multiple Sclerosis Patients Receiving Mitoxantrone Chemotherapy Correlated with Quality of Life Indicators.
  Moore LA, Kaufman M, Edinger A, Sigma Theta Tau International Nursing Honorary Society, 39th Annual Conference, Baltimore, MD, 1/2/2007
• Preliminary CHOICE results: a phase 2, randomized, double-blind, placebo-controlled multicentre study of subcutanieous daclizumab in patients with active, relapsing fo...
  Montalban X, Wynn D, Kaufman M, Wang M, Fong A, ECTRIMS, Prague, Czech Republic, 1/1/2007
• Differential effects of depression and anxiety on measures sensitive to cognitive slowing in multiple sclerosis. Poster
  Johnson, S.K., Holden, J., Diamond, B., Kaufman, M, Archives of Clinical Neuropsychology; 24th Annual Meeting of the National Academy of Neuropsychology, Seattle, WA, 1/1/2004
• New technique to manage betaseron injection site reactions.
  Moore L, Kaufman M, Algozzine R, Rosser C, Irish N, Martin M, MS Trust Sixth Annual Conference, Harrogate, England, 1/1/2002
• The impact of ethnicity, symptom severity, stressors and resources on quality of life in multiple sclerosis.
  Johnson SK, Sargent C, Kaufman M, Society for Behavioral Medicine, 22nd Annual Meeting, Seattle, WA, 1/24/2001
• Safety and tolerabiltiy of the combination of interferon beta-1a and oral cyclophosphamide for patients with multiple sclerosis.
  Kaufman MD, Norton J, Sonnenfeld G, Neurology; 53rd American Academy of Neurology Annual Meeting, Philadelphia, PA, 1/1/2001
• Multiple Sclerosis: Severity and Progression Rate in African Americans Compared with Caucasians.
  Norton HJ, Bivens J, Johnson S, Moyer D, Kaufman MD, Neurology; 53rd American Academy of Neurology Annual Meeting, Philadelphia, PA, 1/1/2001
• Comparison of quantitative sensory testing to the standard clinical examination and self-assessment. Poster
  Kaufman MD, Lutz D, Norton J, Consortium of Multiple Sclerosis Centers, Annual Meeting, Halifax, Nova Scotia, Canada, 1/22/2000
• Lack of detection of Chlamydia Pneumoniae by PCR and tissue culture in cerebrospinal fluids from patients with multiple sclerosis, other neurological conditions, and n...
  Zuzak K, Theodore M, Kaufman MD, Wagar E, Myers L, Quinn TC, Gaydos CA, European Chlamydia meeting, Helsinki, Finland, 1/1/2000
• Focal destructive brainstem demyelination: A report of five cases. Poster
  Kaufman MD, Int. J. MSCare; Consortium of Multiple Sclerosis Centers, Annual Meeting, Halifax, Nova Scotia, Canada, 1/1/2000
• Join now to see all

Other

• CME article: How to Choose an Immunomodulator in 2010 and Beyond. 
  Kaufman MD
  http://cme.medscape.com/viewprogram/31525
  1/25/2010